Xvivo Perfusion (Q3 Initial take): Strong sales growth, boosted by Thoracic - Redeye ...
Q3e sales +6%, with 5% organic growth* Raised EBITA driven by new contracts* Share trading at 15x '26e EV/EBITA, goes to 9x ...
Sequential sales decline, but order activity has improved* We lift '26e/'27e/'28e EBIT by 9%/7%/6%* 14-11x '26e-'27e EV/EBIT ...
Q3e: sequential step-up in organic growth and margin* M&A the main driver behind our EBITA upgrades* Two new acquisitions end ...
ATOSS will release preliminary Q3 figures on Friday. We expect another strong quarter, which should make the margin guidance ...
We lower total ‘27e-‘28e sales by 4%, see break-even in FY'27e* Recycling +66% y-o-y, record trial activity and growing ...
Demand stabilising, but reduction in FTEs a headwind* We cut adj. EBITA by 6% for '26e and 10% for '27e* Trading at ...
EBIT -20% vs. ABGSCe on timing and tech costs* We lower ‘26e-‘28e sales by 3% and EBIT adj. by 4%/6%/5%* EU vote outcome ...
Q3e EBITDA of NOK 10m, top line flat q-o-q* Meijer kicks off the US opportunity* Fair value range of NOK 8-18 per share ...
* Q3e: Sales of SEK 1,178m, adj. EBIT of SEK 46m * US demand backdrop remains robust * Trading at 11-9x '26e-'27e P/E ...
BofA höjer riktkursen för EQT till 405 kronor, 'undervärderat efter stark kapitalanskaffning' ...
We forecast net sales of SEK 178m in Q3'26e* DTC-related cost ramp-up now in comps, EBITA +3% y-o-y* We reiterate our fair ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results